Buscar
Mostrando ítems 31-37 de 37
Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era
(Elsevier, 2020-06-08)
[Abstract] Purpose: To describe the epidemiology of critical disease in HIV-infected patients during the current highly active antiretroviral therapy (HAART) era and to identify hospital mortality predictors.
Methods: ...
Hepatitis E 3ra genotype infection in people living with HIV in Spain
(Frontiers, 2020-09-11)
[Abstract] Background: The objective of our study was to assess the prevalence and incidence of HEV in people living with HIV (PLWH) in a Spanish national cohort.
Methods: Retrospective longitudinal study including PLWH ...
Despistaje de la infección por el virus de inmunodeficiencia humana en Atención Primaria mediante indicadores de sospecha: estudio DIVAPIS
(Sociedade Galega de Medicina Interna (SOGAMI), 2019-10)
[Resumen] Introducción: El diagnóstico precoz de la infección por VIH es fundamental
para mejorar el pronóstico de la enfermedad y evitar nuevos contagios. Atención Primaria (AP), al ser el primer nivel asistencial al que ...
DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: a retrospective study
(Springer, 2019-10-23)
[Abstract] Background. Most of the circulating Vitamin D (VitD) is transported bound to vitamin D-binding protein (DBP), and several DBP single nucleotide polymorphisms (SNPs) have been related to circulating VitD concentration ...
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
(Wiley, 2017-07-16)
[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of ...
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
(BMJ, 2021-10-14)
[Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients.
Objectives: This study evaluated ...
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
(BMJ, 2020-10-13)
[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ...